UNICREDIT BANK/CALL/BRISTOL-MYERS SQUIBB/60/0.1/15.01.25 | Market Closed - BOERSE MUENCHEN 15:41:49 2024-07-01 EDT | ||
| 0.018 EUR | 0.00% |
|
| 1 month | -25.00% | ||
| 3 months | -92.17% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about BRISTOL-MYERS SQUIBB COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 24-07-01 | 0.018 | 0.00% |
| 24-06-28 | 0.018 | -5.26% |
| 24-06-27 | 0.019 | -20.83% |
| 24-06-26 | 0.024 | +4.35% |
| 24-06-25 | 0.023 | +4.55% |
Real-time BOERSE MUENCHEN
Last update July 01, 2024 at 03:41 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | BRISTOL-MYERS SQUIBB COMPANY |
| Issuer | 
UniCredit
|
| WKN | HC96FH |
| ISIN | DE000HC96FH8 |
| Date issued | 2023-09-11 |
| Strike | 60 $ |
| Maturity | 2025-01-15 (198 Days) |
| Parity | 10 : 1 |
| Emission price | 0.74 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.73 € |
|---|---|
| Lowest since issue | 0.001 € |
| Spread | 0.009 € |
| Spread % | 34.62% |
Company Profile
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques.
The United States account for 70.1% of net sales.
Sector
-
Ratings for Bristol-Myers Squibb Company
Trading Rating
Investor Rating
ESG Refinitiv
B
Consensus: Bristol-Myers Squibb Company
Sell
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
41.3
USD
Average target price
53.19
USD
Spread / Average Target
+28.80%
- Stock Market
- Warrants
- Warrant
